+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinoblastoma - Pipeline Review, H1 2020

  • ID: 5024715
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 67 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Canget BioTekpharma LLC
  • PepVax Inc
  • Seneca Therapeutics Inc
  • VCN Biosciences SL
  • MORE
Retinoblastoma - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1 and 6 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Canget BioTekpharma LLC
  • PepVax Inc
  • Seneca Therapeutics Inc
  • VCN Biosciences SL
  • MORE
  • Introduction
  • Report Coverage
  • Retinoblastoma - Overview
  • Retinoblastoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Retinoblastoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinoblastoma - Companies Involved in Therapeutics Development
  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Canget BioTekpharma LLC
  • Innovation Pharmaceuticals Inc
  • PepVax Inc
  • Seneca Therapeutics Inc
  • Targeted Therapy Technologies LLC
  • VCN Biosciences SL
  • Y-mAbs Therapeutics Inc
  • Retinoblastoma - Drug Profiles
  • ALRN-6924 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APN-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-761 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-7729 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-7N1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Kevetrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • omburtamab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SVV-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • topotecan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VCN-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
  • Featured News & Press Releases
  • Jan 24, 2019: SJD Barcelona Children’s Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01
  • Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
  • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
  • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
  • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
  • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
  • Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Retinoblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Retinoblastoma - Pipeline by Aileron Therapeutics Inc, H1 2020
  • Retinoblastoma - Pipeline by APEIRON Biologics AG, H1 2020
  • Retinoblastoma - Pipeline by Canget BioTekpharma LLC, H1 2020
  • Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2020
  • Retinoblastoma - Pipeline by PepVax Inc, H1 2020
  • Retinoblastoma - Pipeline by Seneca Therapeutics Inc, H1 2020
  • Retinoblastoma - Pipeline by Targeted Therapy Technologies LLC, H1 2020
  • Retinoblastoma - Pipeline by VCN Biosciences SL, H1 2020
  • Retinoblastoma - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
  • Retinoblastoma - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Retinoblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Canget BioTekpharma LLC
  • Innovation Pharmaceuticals Inc
  • PepVax Inc
  • Seneca Therapeutics Inc
  • Targeted Therapy Technologies LLC
  • VCN Biosciences SL
  • Y-mAbs Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll